Waters
Waters Corporation
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.2B
Operating marginCalculated
25.4%
Net assets to total assetsCalculated
50.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
25.4%
Growth (revenue, 4-year average)
★★☆☆☆position among all companies
3.2%
Capital efficiency
★★★★☆position among all companies
25.1%
Revenue and profit
Performance, financial position and capital allocation
Waters
Recent performance trends
Waters
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$2.8 billion | US$3.0 billion | US$3.0 billion | US$3.0 billion | US$3.2 billion |
| Operating income | US$0.8 billion | US$0.9 billion | US$0.8 billion | US$0.8 billion | US$0.8 billion |
| Net income | Could not be retrieved | US$0.7 billion | US$0.6 billion | US$0.6 billion | US$0.6 billion |
| Total assets | US$3.1 billion | US$3.3 billion | US$4.6 billion | US$4.6 billion | US$5.1 billion |
| Shareholders' equity | US$0.4 billion | US$0.5 billion | US$1.2 billion | US$1.8 billion | US$2.6 billion |
| Net cash provided by (used in) operating activities | US$0.7 billion | US$0.6 billion | US$0.6 billion | US$0.8 billion | US$0.7 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.1 billion | US$-1.4 billion | US$-0.1 billion | US$-0.2 billion |
| Net cash provided by (used in) financing activities | US$-0.4 billion | US$-0.5 billion | US$0.8 billion | US$-0.7 billion | US$-0.2 billion |
| Cash and cash equivalents | US$0.5 billion | US$0.5 billion | US$0.4 billion | US$0.3 billion | US$0.6 billion |
Revenue scale in the same industry
Waters
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 36 companies
- 40 BrukerFY Dec 2025 US$3.4B
- 41 TeradyneFY Dec 2025 US$3.2B
- 42 WatersThis companyFY Dec 2025 US$3.2B
- 43 MiniMed GroupFY Apr 2026 US$3.1B
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.7 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$88.14 million | Consolidated | Disclosed |
| Net assets | US$2.6 billion | Consolidated | Disclosed |
| Net sales | US$3.2 billion | Consolidated | Disclosed |
| Operating income | US$0.8 billion | Consolidated | Disclosed |
| Net income | US$0.6 billion | Consolidated | Disclosed |
| Total assets | US$5.1 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$14.67 million | Consolidated | Disclosed |
| Operating margin | 25.4% | Consolidated | Calculated |
| Net assets to total assets | 50.5% | Consolidated | Calculated |
| Net margin | 20.3% | Consolidated | Calculated |
| Return on equity | 25.1% | Consolidated | Calculated |